465
Participants
Start Date
February 28, 2007
Primary Completion Date
December 31, 2008
Study Completion Date
April 30, 2009
Telaprevir
tablet
Ribavirin
tablet
Pegylated Interferon Alfa 2a
Solution for injection
Matching Placebo
Tablet
Cedars-Sinai Medical Center, Los Angeles
Birmingham Gastroenterology Associates, Birmingham
USC, Los Angeles
Kaiser Permanente Hepatology Research, San Diego
University of California, San Diego, San Diego
University of California San Francisco, San Francisco
University of Colorado Health Sciences Center, Denver
Englewood
Bardenton
University of Florida, Gainesville
Borland-Groover Clinic, Jacksonville
Mayo Clinic Jacksonville, Jacksonville
Miami
University Hepatitis Center at Bach & Godofsky, Sarasota
Atlanta
Chicago
Indianapolis
Gulf Coast Research, LLC, Baton Rouge
Virology Treatment Center, Maine Medical Center, Portland
Johns Hopkins University, Baltimore
Beth Isreal Deaconess Medical Center, Boston
Henry Ford Hospital, Detroit
Saint Louis University, St Louis
Omaha
Albuquerque
North Shore University Hospital, Manhasset
New York
Durham
University Internal Medicine Associates, Inc., Cincinnati
Cleveland Clinic, Cleveland
Hershey
Pittsburgh
Columbia Gastroenterology Associates, PA, Columbia
Memphis Gastroenterology Group, Germantown
Liver Institute at Methodist Dallas, Dallas
Advanced Liver Therapies, Houston
Alamo Medical Research, San Antonio
Annandale
Metropolitan Research, Fairfax
Richmond
Seattle
Edmonton
BC Hepatitis Program, Vancouver
Winnipeg
Toronto Western Hospital, Toronto
Toronto
Universitatsmedizin Berlin, Berlin
University Clinic Frankfurt, Department of Internal Medicine, Frankfurt
Academic Medical Center, Amsterdam
Leiden University Medical Center, Leiden
Erasmus MC University Medical Center, Rotterdam
Santurce
University of Calgary Medical Clinic - Health Science Centre, Calgary
Vertex Pharmaceuticals Incorporated
INDUSTRY